Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 122

1.

Pharmacogenomics of endocrine therapy in breast cancer.

Weinshilboum R.

Adv Exp Med Biol. 2008;630:220-31. Review.

PMID:
18637494
[PubMed - indexed for MEDLINE]
2.

The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.

Fleeman N, Martin Saborido C, Payne K, Boland A, Dickson R, Dundar Y, Fernández Santander A, Howell S, Newman W, Oyee J, Walley T.

Health Technol Assess. 2011 Sep;15(33):1-102. doi: 10.3310/hta15330. Review.

PMID:
21906462
[PubMed - indexed for MEDLINE]
Free Article
3.

CYP2D6 and tamoxifen: DNA matters in breast cancer.

Hoskins JM, Carey LA, McLeod HL.

Nat Rev Cancer. 2009 Aug;9(8):576-86. doi: 10.1038/nrc2683. Review.

PMID:
19629072
[PubMed - indexed for MEDLINE]
4.

Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?

Higgins MJ, Rae JM, Flockhart DA, Hayes DF, Stearns V.

J Natl Compr Canc Netw. 2009 Feb;7(2):203-13. Review.

PMID:
19200418
[PubMed - indexed for MEDLINE]
5.

CYP2D6 polymorphisms and the impact on tamoxifen therapy.

Beverage JN, Sissung TM, Sion AM, Danesi R, Figg WD.

J Pharm Sci. 2007 Sep;96(9):2224-31. Review.

PMID:
17518364
[PubMed - indexed for MEDLINE]
6.

Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer.

Dezentjé VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H.

Clin Cancer Res. 2009 Jan 1;15(1):15-21. doi: 10.1158/1078-0432.CCR-08-2006. Review.

PMID:
19118028
[PubMed - indexed for MEDLINE]
Free Article
7.

Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.

Singh MS, Francis PA, Michael M.

Breast. 2011 Apr;20(2):111-8. doi: 10.1016/j.breast.2010.11.003. Epub 2010 Dec 24. Review.

PMID:
21185724
[PubMed - indexed for MEDLINE]
8.

Pharmacogenomics of tamoxifen therapy.

Brauch H, Mürdter TE, Eichelbaum M, Schwab M.

Clin Chem. 2009 Oct;55(10):1770-82. doi: 10.1373/clinchem.2008.121756. Epub 2009 Jul 2. Review.

PMID:
19574470
[PubMed - indexed for MEDLINE]
Free Article
9.

Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach?

Brauch H, Jordan VC.

Eur J Cancer. 2009 Sep;45(13):2274-83. doi: 10.1016/j.ejca.2009.05.032. Epub 2009 Jul 9. Review.

PMID:
19592233
[PubMed - indexed for MEDLINE]
10.

Tamoxifen metabolism and its effect on endocrine treatment of breast cancer.

Briest S, Stearns V.

Clin Adv Hematol Oncol. 2009 Mar;7(3):185-92. Review.

PMID:
19398943
[PubMed - indexed for MEDLINE]
11.

CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance.

Higgins MJ, Stearns V.

Curr Oncol Rep. 2010 Jan;12(1):7-15. doi: 10.1007/s11912-009-0076-5. Review.

PMID:
20425602
[PubMed - indexed for MEDLINE]
12.

Pharmacogenetics of anti-estrogen treatment of breast cancer.

Del Re M, Michelucci A, Simi P, Danesi R.

Cancer Treat Rev. 2012 Aug;38(5):442-50. doi: 10.1016/j.ctrv.2011.08.003. Epub 2011 Sep 13. Review.

PMID:
21917382
[PubMed - indexed for MEDLINE]
13.

Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.

Goetz MP, Kamal A, Ames MM.

Clin Pharmacol Ther. 2008 Jan;83(1):160-6. Epub 2007 Sep 19. Review.

PMID:
17882159
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Tamoxifen and CYP2D6: a contradiction of data.

Hertz DL, McLeod HL, Irvin WJ Jr.

Oncologist. 2012;17(5):620-30. doi: 10.1634/theoncologist.2011-0418. Epub 2012 Apr 24. Review.

PMID:
22531359
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Zhou SF.

Clin Pharmacokinet. 2009;48(11):689-723. doi: 10.2165/11318030-000000000-00000. Review.

PMID:
19817501
[PubMed - indexed for MEDLINE]
16.

Factors predictive of response to hormone therapy in breast cancer.

Rastelli F, Crispino S.

Tumori. 2008 May-Jun;94(3):370-83. Review.

PMID:
18705406
[PubMed - indexed for MEDLINE]
17.

Should CYP2D6 inhibitors be administered in conjunction with tamoxifen?

Zembutsu H, Sasa M, Kiyotani K, Mushiroda T, Nakamura Y.

Expert Rev Anticancer Ther. 2011 Feb;11(2):185-93. doi: 10.1586/era.10.228. Review.

PMID:
21342038
[PubMed - indexed for MEDLINE]
18.

Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy.

Lyon E, Gastier Foster J, Palomaki GE, Pratt VM, Reynolds K, Sábato MF, Scott SA, Vitazka P; working group of the Molecular Genetics Subcommittee on behalf of the American College of Medical Genetics and Genomics ACMG) Laboratory Quality Assurance Committee.

Genet Med. 2012 Dec;14(12):990-1000. doi: 10.1038/gim.2012.108. Epub 2012 Sep 6. Review.

PMID:
22955113
[PubMed - indexed for MEDLINE]
19.

Pharmacogenomics of tamoxifen and irinotecan therapies.

Algeciras-Schimnich A, O'Kane DJ, Snozek CL.

Clin Lab Med. 2008 Dec;28(4):553-67. doi: 10.1016/j.cll.2008.05.004. Review.

PMID:
19059062
[PubMed - indexed for MEDLINE]
20.

Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters.

Kiyotani K, Mushiroda T, Nakamura Y, Zembutsu H.

Drug Metab Pharmacokinet. 2012;27(1):122-31. Epub 2011 Nov 1. Review.

PMID:
22041137
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk